Xencor (XNCR) Rebounds Sharply, Is It Still A Bargain?

Xencor (XNCR) has attracted investor attention after recent share price moves, with the stock closing at $15.85 and showing double digit total returns over the past year despite earlier multi year declines.

See our latest analysis for Xencor.

Recent trading reflects a sharp rebound in interest, with Xencor’s 30 day share price return of 33.98% and 90 day share price return of 27.62% contrasting with a 5 year total shareholder return that remains down 52.13%. This suggests momentum has picked up after a prolonged period of weaker long term outcomes.

If Xencor’s move has you looking beyond a single biopharma stock, it can be a useful time to scan other healthcare names and see which are gaining traction through the 41 healthcare AI stocks.

After Xencor’s sharp rebound and still weak longer term record, the key issue now is whether the current price still compensates you for the risks involved, or whether most of the upside has already been recognised in the valuation.

Most Popular Narrative: 44.4% Undervalued

The most followed narrative puts Xencor’s fair value at $28.50 per share compared with the recent close at $15.85, framing the stock as materially underpriced based on long term pipeline expectations and modeled financial outcomes.

The robust and flexible XmAb platform allows for modular drug development and the creation of differentiated assets, expected to reduce development costs and timelines, directly benefiting future operating margins and net profitability.
Clinical trial strategy emphasizes efficient dose ranging and selection, ongoing biomarker efforts, and combination therapy optionality, positioning the company to respond rapidly to evolving standards of care and maximize the commercial potential of its pipeline, with positive implications for recurring revenue and ultimate earnings leverage.

Read the complete narrative.

Want to see how that platform story translates into hard numbers? The narrative leans heavily on ambitious revenue expansion, margin improvement, and a premium future earnings multiple that most investors would not immediately expect. Curious which specific assumptions bridge today’s losses to that target valuation and how they interact over time?

Result: Fair Value of $28.50 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this narrative can unravel if Xencor’s TL1A programs struggle to stand out in a crowded field or if costly late stage trials slip or disappoint.

Find out about the key risks to this Xencor narrative.

Another View: What Xencor’s Sales Multiple Is Telling You

While the most popular Xencor narrative leans on a $28.50 fair value, today’s P/S ratio of 12.1x paints a different picture. It sits slightly above the US Biotechs industry at 12x, and far above the fair ratio of 0.7x. This suggests meaningful valuation risk if sentiment cools.

For a closer look at how this pricing compares with the numbers, including how that fair ratio is derived, check the valuation breakdown through the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed sentiment surrounding this Xencor story, this is a good moment to review the full picture yourself, including the 1 key reward and 1 important warning sign

Looking for more investment ideas beyond Xencor?

If the Xencor story has sharpened your focus, use this momentum to widen your watchlist and uncover other stocks that could fit your approach.

• Spot potential mispricings early by scanning the 44 high quality undervalued stocks that combine quality fundamentals with prices many investors may be overlooking.
• Build a steadier income stream by reviewing the 9 dividend fortresses designed for investors who want higher yields backed by fundamental data.
• Strengthen the defensive side of your portfolio by checking the 76 resilient stocks with low risk scores that score well on resilience and downside protection.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com